Durable complete leptomeningeal and intracerebral responses to first-line Pembrolizumab in highly-selected Non-small cell lung cancer patients

Intracranial metastases occur in 30–50% of patients with Non-small cell lung cancer (NSCLC) and have a poor prognosis despite current therapies utilising systemic chemotherapy, neurosurgery and radiotherapy. In contrast to the robust evidence for using immunotherapy to treat intracranial metastases in melanoma, evidence for intracranial responses in NSCLC are limited to retrospective studies and case reports describing third-line immunotherapy treatment.